The diabetes drug delivery devices market is projected to grow at an annualized rate of ~9%, till 2030

Author : kevin987
Publish Date : 2021-02-17 12:47:22


Roots Analysis has done a detailed study on Diabetes Drug Delivery Devices Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 240+ page report, which features 50+ figures and 70+ tables, please visit this link

 

Key Market Insights

  • More than 80 devices are available / under development for the delivery of various pharmacological interventions, via a variety of routes, for the treatment of diabetes
  • The market landscape is fragmented, featuring both new entrants (small companies) and established players (mid-large sized enterprises); the US is currently considered to be a hub of innovation related to insulin delivery devices
  • Leveraging their expertise, stakeholders within this domain are developing a myriad of invasive and non-invasive diabetes drug delivery devices that can administer drugs through different routes
  • In order to achieve an edge over competing players, drug delivery device developers are actively focusing on the integration / inclusion of novel / advanced features in their respective products / offerings
  • Over 60 deals have been inked in the past five years; majority of the reported collaborations focused on the integration of delivery devices with CGM systems
  • Several big pharmaceutical players are actively expanding their existing capabilities in order to augment their respective product portfolios and also comply to evolving industry benchmarks
  • Given the rising incidence of diabetes and a growing pipeline of innovative pharmacological interventions to treat the condition, the market for antidiabetic drug delivery devices is poised to grow at a CAGR of 8%, till 2030
  • The projected market opportunity is anticipated to be well-distributed across the different types of diabetes, device usability and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/diabetes-drug-delivery-devices-market.html

 

Table of Contents

 

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY

 

3.          INTRODUCTION

3.1.       Chapter Overview

3.2.       An Overview of Diabetes

3.2.1.    Classification of Diabetes

3.2.1.1. Type 1 Diabetes

3.2.1.2. Type 2 Diabetes

 

3.3.       Route of Administration for Diabetes Drugs

3.3.1.    Buccal Route

3.3.2.    Inhalation Route

3.3.3.    Intradermal Route

3.3.4.    Intramuscular Route

3.3.5.    Intranasal Route

3.3.6     Oral Route

3.3.7.    Subcutaneous Route

 

 

3.4.       Key Challenges Associated with Delivery of Diabetes Drugs

3.5.       Diabetes Drug Delivery Devices

3.5.1.    Implants

3.5.2.    Inhalation Devices

3.5.3.    Insulin Ports

3.5.4.    Insulin Pumps

3.5.5.    Jet Injectors

3.5.6.    Microneedle Patches

3.5.7.    Nasal Delivery Devices

3.5.8.    Pen-Injectors / Autoinjectors

 

3.6        Concluding Remarks

 

4.          CURRENT MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Diabetes Drug Delivery Devices: Overall Market Landscape

4.2.1.    Analysis by Type of Device

4.2.2.    Analysis by Stage of Development

4.2.3.    Analysis by Route of Administration

4.2.4.    Analysis by Mode of Drug Delivery

4.2.5.    Analysis by Needle Attributes

4.2.6.    Analysis by Type of Drug Delivery System

4.2.7.    Analysis by Drug Administration Speed

4.2.8.    Analysis by Device Usability

4.2.9.    Analysis by Diabetes Type

4.2.10.  Analysis by Type of Drug

 

4.3.       Diabetes Drug Delivery Devices: List of Developers

4.3.1.    Analysis by Type of Developer

4.3.2.    Analysis by Year of Establishment

4.3.3.    Analysis by Company Size

4.3.4.    Analysis by Location of Headquarters

4.3.5.    Leading Manufacturers: Analysis by Number of Products

 

5.         PRODUCT COMPETITIVE ANALYSIS
5.1.       Chapter Overview
5.2.       Assumption and Methodology

5.3.       Product Competitive Analysis: Diabetes Drug Delivery Devices
 

6.          PARTNERSHIP AND COLLABORATIONS

6.1.       Chapter Overview

6.2.       Partnership Models

6.3.       Diabetes Drug Delivery Devices: List of Partnerships and Collaborations

6.3.1.    Analysis by Year of Partnership

6.3.2.    Analysis by Type of Partnership

6.3.3.    Analysis by Year and Type of Partnership

6.3.4.    Analysis by Type of Device

6.3.5.    Most Active Players: Analysis by Number of Partnerships

6.3.6.     Geographical Analysis

6.3.6.1.  Region-wise Distribution

6.3.6.2.  Country-wise Distribution

 

7.           COMPANY PROFILES

7.1.        Chapter Overview

7.2.        Bigfoot Biomedical

7.2.1.     Company Overview

7.2.2.     Diabetes Drug Delivery Device Portfolio

7.2.3.     Recent Developments and Future Outlook

 

7.3.        Debiotech

7.3.1.     Company Overview

7.3.2.     Diabetes Drug Delivery Device Portfolio

7.3.3.     Recent Developments and Future Outlook

 

7.4.        Haselmeier

7.4.1.     Company Overview

7.4.2.     Diabetes Drug Delivery Device Portfolio

7.4.3.     Recent Developments and Future Outlook

 

7.5.        Medtronic

7.5.1.     Company Overview

7.5.2.     Diabetes Drug Delivery Device Portfolio

7.5.3.     Recent Developments and Future Outlook

 

7.6.        Novo Nordisk

7.6.1.     Company Overview

7.6.2.     Diabetes Drug Delivery Device Portfolio

7.6.3.     Recent Developments and Future Outlook

 

7.7.        Roche

7.7.1.     Company Overview

7.7.2.     Diabetes Drug Delivery Device Portfolio

7.7.3.     Recent Developments and Future Outlook

 

7.8.        SOOIL

7.8.1.     Company Overview

7.8.2.     Diabetes Drug Delivery Device Portfolio

7.8.3.     Recent Developments and Future Outlook

 

7.9.        Ypsomed

7.9.1.     Company Overview

7.9.2.     Diabetes Drug Delivery Device Portfolio

7.9.3.     Recent Developments and Future Outlook

 

 

8.           DIABETES DRUG DELIVERY DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS

8.1.        Chapter Overview

8.2.        Scope and Methodology

8.3.        Initiatives of Big Pharma Players

8.3.1.     Analysis by Diversity in Device Portfolio

8.3.2.     Analysis by Phase of Development

8.3.3.     Analysis by Diabetes Type

8.3.4.     Analysis by Type of Drug

8.3.5.     Analysis by Number of Partnerships

8.4.        Benchmark Analysis of Big Pharma Players

8.4.1.     Spider Web Analysis: Company A

8.4.2.     Spider Web Analysis: Company B

8.4.3.     Spider Web Analysis: Company C

8.4.4.     Spider Web Analysis: Company D

8.4.5.     Spider Web Analysis: Company E

8.4.6.     Spider Web Analysis: Company F

 

9.           MARKET SIZING AND OPPORTUNITY ANALYSIS

9.1.        Chapter Overview

9.2.        Forecast Methodology and Assumptions

9.3.        Overall Diabetes Drug Delivery Devices Market, 2020-2030

9.3.1.     Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Type of Device

9.3.2.     Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Route of Administration

9.3.3.     Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Diabetes Type

9.3.4.     Diabetes Drug Delivery Devices Market, 2020-2030: Distribution by Device Usability

9.3.5.     Diabetes Drug Delivery Devices Market, 2020-2030: Geographical Distribution

9.3.5.1.  Diabetes Drug Delivery Devices Market in North America, 2020-2030

9.3.5.2.  Diabetes Drug Delivery Devices Market in Europe, 2020-2030



Catagory :general